GSTM1 and sickle cell disease: The role of 2,3-DPG in O2 unloading has led to the development of synthetic allosteric effectors aimed at modulating Hb oxygen affinity in clinical contexts, especially for the treatment of ischaemia-related diseases such as sickle cell disease(68).